Gastric tubular reconstruction (GTR) is a commonly used anti-reflux reconstruction method after proximal gastrectomy. This study compares the short-term efficacy and quality of life (QoL) between totally laparoscopic proximal gastrectomy using an endoscopic linear stapler with laparoscopic-assisted proximal gastrectomy using a circular stapler for GTR to provide a reference for the rational selection of anastomotic devices in clinical practice. A retrospective analysis of 111 upper gastric cancer patients undergoing laparoscopic proximal gastrectomy with GTR was conducted from October 2021 to April 2024. Patients were divided into CS (48 cases) and LS (63 cases) groups. Baseline characteristics, perioperative indicators, and short-term efficacy were compared. QoL was assessed using EORTC QLQ-C30 and QLQ-STO22 at three months postoperatively, and gastroscopy at six months evaluated reflux esophagitis. No significant baseline differences were found. The LS group had less intraoperative bleeding, faster recovery, and shorter hospital stay compared to CS (P < 0.05). No differences in operation time, lymph node dissection, complication rates, or nutritional status were observed (P > 0.05). QoL and reflux esophagitis incidence were similar between groups (P > 0.05). Compared with CS for GTR, the LS group had less intraoperative bleeding, faster postoperative recovery and shorter hospital stay. The QoL, nutritional status and incidence of reflux esophagitis of the two groups were comparable.

Postoperative recurrence remains common in patients with Siewert type II/III gastroesophageal junction adenocarcinoma (AEG), and conventional TNM staging provides limited individualized prognostic information. This study aimed to develop and validate a composite Nutritional Risk Index and Hemoglobin-to-Platelet Ratio (NRI-HPR) score for predicting recurrence and survival. A total of 270 patients who underwent curative gastrectomy between 2011 and 2015 were included as the training cohort, and 117 patients treated between 2020 and 2023 were enrolled as an independent validation cohort. Patients were stratified into three NRI-HPR score groups according to predefined cutoffs. Survival outcomes and recurrence patterns were analyzed using Kaplan–Meier and Cox regression analyses. Prognostic nomograms incorporating NRI-HPR were constructed and validated. In the training cohort, 5-year recurrence-free survival (RFS) rates were 79.6

Bioadhesives represent promising alternatives to sutures towards gastric perforation management, however, significant challenges persist concerning instant wet adhesion and durable stability in gastric perforation sealing, particularly in direct contacting with acidic gastric fluids on large perforation injuries. Here we report an injectable acid-tolerant hydrogel composed of FDA-approved components for sutureless repair of large gastric defects. The hydrogel displays rapid in situ gelation, instant wet adhesion, and high burst pressure for efficient sealing despite excessive mechanical challenges, tissue irregularities and gastric juices. The enhanced hydrogen bonding interactions among amide-linked skeleton enable robust acid-tolerant interfaces to accommodate durable adhesion under the fluidically, chemically and mechanically dynamic in-vivo environments. A larger-scale porcine gastric perforation is applied to validate the sealing efficacy via a combined laparoscopic-endoscopic technique. The negligible postoperative adhesion, suppressed inflammation and interference-free transcriptome and microbiome verify the therapeutic outcomes. The proposed bioadhesives hold great promise for clinical treatment of digestive diseases.

BackgroundAlthough early gastric cancer (EGC) is generally limited to the mucosal and submucosal layers, lymph node metastasis can still occur, which may worsen the prognosis, particularly when the number of examined lymph nodes (ELNs) is inadequate. This study introduces log odds of positive lymph nodes (LODDS) as a prognostic factor and integrates it with machine learning to improve survival predictions in T1N+ gastric cancer (GC).MethodsThis retrospective study used data from the Surveillance, Epidemiology, and End Results (SEER) Program and an independent validation cohort from the Chinese People’s Liberation Army General Hospital First Medical Center. Predictive factors were selected using LASSO regression and multivariate Cox regression. Cox proportional-hazards (CoxPH), random survival forest (RSF), and XGBoost models were developed to predict overall survival (OS). Model interpretability and feature importance were evaluated using the SHapley Additive exPlanations (SHAP) method.ResultsA total of 419 T1N+ GC patients from the SEER database and 193 from our institution were included in the study. LODDS staging was identified as an independent prognostic factor, demonstrating superior discriminatory power compared to N staging (C-index 0.65 vs. 0.57). Based on the Brier score, area under the ROC curve (AUC), and C-index, the RSF model outperformed both the Cox model and XGBoost model. The RSF model achieved a C-index of 0.79 in the training cohort and 0.80 in the validation cohort, indicating favorable discrimination and calibration, with Brier scores below 0.25.ConclusionsIntegrating LODDS staging into the RSF model, alongside other clinical features, provides a highly accurate tool for survival prediction in T1N+ GC patients.

Neoadjuvant chemotherapy (NAC) combined with gastrectomy has been a standard therapeutic strategy for resectable gastric cancer (GC). However, it remains unclear whether postoperative adjuvant chemotherapy (AC) brings better survival in ypTNM stage I GC patients. Data on ypTNM stage I GC patients with or without AC following systemic NAC and radical gastrectomy were retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2021. Inverse probability of treatment weighting (IPTW) was used to balance covariates. Overall survival (OS) and cancer-specific survival (CSS) were assessed through Kaplan-Meier and Cox proportional hazards models. Two nomograms were developed to predict OS and CSS of patients with ypTNM stage I GC who received AC. 661 patients met the inclusion criteria, 230 received AC and 431 were AC nonuser. AC was significantly associated with improved OS (weighted HR = 0.63, 95

Endoscopic procedures often subject endoscopists to heavy workloads and significant radiation exposure, while inappropriate maneuvers can potentially cause patient discomfort or clinical complications. This work presents a novel robotic endoscope system that integrates shape perception and depth estimation for autonomous navigation in complex gastrointestinal (GI) environments. The system features a custom-designed endoscope integrated with the fiber Bragg gratings (FBGs) sensor for shape tracking and a monocular camera for visual input. The FBGs enable real-time endoscopic shape perception through precisely reconstructing the endoscopic pose during dynamic interventions. A unified control framework is proposed to enhance the system's generality by integrating depth estimation and shape perception. The direction and velocity of endoscopic intervention are adaptively synchronized. Highly realistic GI phantoms and in vivo animal experiments demonstrate that the system successfully performs autonomous interventions in complex GI environments, with a bending angle error of 2.75 degrees and a mean pixel tracking error of 74.2 pixels. This work advances robotic endoscopes by enhancing perceptual accuracy and autonomy, demonstrating significant potential for clinical applications in endoscopic examinations and procedures.

Using data samples of 983.0 fb−1 and 427.9 fb−1 accumulated with the Belle and Belle II detectors operating at the KEKB and SuperKEKB asymmetric-energy e+e− colliders, singly Cabibbo-suppressed decays Ξ_c^+→ pK_S^0 , Ξ_c^+→Λπ^+ , and Ξ_c^+→Σ^0π^+ are observed for the first time. The ratios of branching fractions of Ξ_c^+→ pK_S^0 , Ξ_c^+→Λπ^+ , and Ξ_c^+→Σ^0π^+ relative to that of Ξ_c^+→Ξ^-π^+π^+ are measured to be [ ℬ(Ξ_c^+→ pK_S^0)/ℬ(Ξ_c^+→Ξ^-π^+π^+)=(2.47± 0.16± 0.07)%,; ℬ(Ξ_c^+→Λπ^+)/ℬ(Ξ_c^+→Ξ^-π^+π^+)=(1.56± 0.14± 0.09)%,; ℬ(Ξ_c^+→Σ^0π^+)/ℬ(Ξ_c^+→Ξ^-π^+π^+)=(4.13± 0.26± 0.22)%. ] Multiplying these values by the branching fraction of the normalization channel, ℬ(Ξ_c^+→Ξ^-π^+π^+)=(2.9± 1.3)% , the absolute branching fractions are determined to be [ ℬ(Ξ_c^+→ pK_S^0)=(7.16± 0.46± 0.20± 3.21)×10^-4,; ℬ(Ξ_c^+→Λπ^+)=(4.52± 0.41± 0.26± 2.03)×10^-4,; ℬ(Ξ_c^+→Σ^0π^+)=(1.20± 0.08± 0.07± 0.54)×10^-3. ] The first and second uncertainties above are statistical and systematic, respectively, while the third ones arise from the uncertainty in ℬ(Ξ_c^+→Ξ^-π^+π^+) .

BACKGROUND In recent years, the global prevalence of gastric cancer (GC) has witnessed a progressive decrease, accompanied by a step-growth in the incidence of gastric signet ring cell carcinoma (GSRCC). As precision medicine concepts progress, GSRCC, a distinct sub-type of GC, has drawn considerable attention from researchers. However, there still persist some controversies regarding the associated research findings. AIM To summarize the current obstacles and potential future directions for research on GSRCC. METHODS To begin with, all literature related to GSRCC published from January 1, 2004 to December 31, 2023 was subjected to bibliometric analysis in this article. Additionally, this paper analyzed the research data using CiteSpace, GraphPad Prism v8.0.2, and VOSviewer, which was obtained from the Web of Science Core Collection database. The analysis results were visually represented. RESULTS This study provided a comprehensive overview of the statistical characteristics of the 995 English articles related to GSRCC, including cited references, authors, journals, countries, institutions, and keywords. The popular keywords and clusters contain "prognosis", "survival", "expression", "histology", and "chemotherapy". CONCLUSION The prognosis, precise definition and classification, as well as chemoresistance of GSRCC, continue to be crucial areas of ongoing research, whose directions are closely tied to advancements in molecular biology research on GSRCC.

Despite recent advances in surgical adhesives as promising alternatives to sutures or staplers for colonic defects and gastrointestinal management, significant challenges persist regarding to excellent biocompatibility, injectability operation, robust tissue adhesion and durable stability in colon environments due to the growing popularity of minimally invasive laparoscopy. In this work, we reported an in situ injectable hydrogel bioadhesive (OSG) consisting of FDA-approved Octa-armed poly (ethylene glycol) succinimidyl glutarate (Octa-PEGSG) and Octa-armed poly (ethylene glycol) amine (Octa-PEG-NH2) polymers for sutureless repair of large colonic defects. The OSG hydrogel was advantageous to rapid injection to cover the whole irregular surfaces via the formation of uniform networks and chemical interface binding, and capable of instant adhesion, high burst pressure, secure sutureless closure and durable compliance in the ex vivo porcine colonic injury models, thus enabling robust wet adhesion interfaces even in direct contact with intestinal fluids and constant colonic peristalsis. In terms of excellent biocompatibility and suitable degradability after a comprehensive evaluation from in vivo and in vitro studies, OSG hydrogel was validated with efficient sutureless colonic repair in a rat-injured model without causing postoperative adhesion, long-term inflammatory response and colonic transcriptome and microbiome interference. Innovatively, we further established large-size (3 cm) of porcine colonic defect models by minimally invasive technique, and verified its therapeutic effect under laparoscopic technology. Overall, the proposed OSG bioadhesive offers a promising clinical alternative to sutures for the treatment of colonic defects.

We measure the time-integrated CP asymmetry in D-0 -> (KSKS0)-K-0 decays reconstructed in e(+)e(-) -> c (c) over bar events collected by the Belle and Belle II experiments. The corresponding data samples have integrated luminosities of 980 and 428 fb(-1), respectively. The D-0 decays are required to originate from the D*(+) -> D-0 pi(+) decay, which determines the charm flavor at production time. A control sample of D-0 -> K+K- decays is used to correct for production and detection asymmetries. The result, (-1.4 +/- 1.3(stat) +/- 0.1(syst))%, is consistent with previous determinations and with CP symmetry.

We present measurements of B → K*(892)γ decays using 365 fb−1 of data collected from 2019 to 2022 by the Belle II experiment at the SuperKEKB asymmetric-energy e+e− collider. The data sample contains (387 ± 6) × 106 Υ(4S) events. We measure branching fractions ( ℬ ) and CP asymmetries ( 𝒜_CP ) for both B0 → K*0γ and B+ → K*+γ decays. The difference in CP asymmetries ( Δ𝒜_CP ) and the isospin asymmetry (∆0+) between these neutral and charged channels are also measured. We obtain the following branching fractions and CP asymmetries: ℬ(B^0→K^*0γ)=(4.14± 0.10± 0.11)×10^-5 , ℬ(B^+→K^*+γ)=(4.04±0.13_-0.15^+0.13)×10^-5 , 𝒜_CP(B^0→K^*0γ)=(-3.3± 2.3± 0.4)% , and Δ𝒜_CP(B^+→K^*+γ)=(-0.7± 2.9± 0.5)% . The measured difference in CP asymmetries is Δ𝒜_CP=(+2.6±3.8± 0.6)% , and the measured isospin asymmetry is ∆0+ = (+4.8 ± 2.0 ± 1.8)

We perform the first search for CP violation in D_(s)^+→K_S^0K^-π^+π^+ decays. We use a combined data set from the Belle and Belle II experiments, which study e+e− collisions at center-of-mass energies at or near the Υ(4S) resonance. We use 980 fb−1 of data from Belle and 428 fb−1 of data from Belle II. We measure six CP-violating asymmetries that are based on triple products and quadruple products of the momenta of final-state particles, and also the particles’ helicity angles. We obtain a precision at the level of 0.5 D^+→K_S^0K^-π^+π^+ decays, and better than 0.3 D_s^+→K_S^0K^-π^+π^+ decays. No evidence of CP violation is found. Our results for the triple-product asymmetries are the most precise to date for singly-Cabibbo-suppressed D+ decays. Our results for the other asymmetries are the first such measurements performed for charm decays.

Neoadjuvant therapy (NAT) effectively downstages locally advanced gastric cancer (LAGC), increasing the proportion of patients achieving ypTNM stage 0–I. However, it is still controversial whether the LAGC patients with better tumor regression (ypTNM stage 0–I) had similar prognosis compared with pTNM I early gastric cancer (EGC) patients or not. This study compared short- and long-term outcomes between ypTNM 0-I LAGC and EGC patients. A retrospective analysis of 1,193 patients with pTNM I EGC or ypTNM 0-I LAGC treated between January 2020 and November 2024 from three medical centers was conducted. Propensity score matching (PSM) at a 1:1 ratio balanced baseline characteristic. Short- and long-term outcomes were compared between groups. After PSM, baseline characteristics were comparable with no significant difference (P > 0.05). The ypTNM 0-I group had longer operative times, greater estimated blood loss, and extended postoperative hospital days compared with pTNM I group (P < 0.05), but no differences in complication rates, recurrence rates, 3-year overall survival (OS: 93.3

BACKGROUND:Immunotherapy has surfaced as a promising therapeutic modality for gastric cancer (GC). A comprehensive review of advancements, current status, and research trends in GC immunotherapy is essential to inform future investigative efforts. AIM:To delineate the trends, advancements, and focal points in immunotherapy for GC. METHODS:We performed a bibliometric analysis of 2906 articles in English concerning GC immunotherapy published from 2000 to December 20, 2023, indexed in the Web of Science Core Collection. Data analysis and visualization were facilitated by CiteSpace (6.1.6R), VOSviewer v.1.6.17, and GraphPad Prism v8.0.2. RESULTS:There has been an increase in the annual publication rate of GC immunotherapy research. China leads in publication volume, while the United States demonstrates the highest citation impact. Fudan University is notable for its citation frequency and publication output. Co-citation analysis and keyword frequency revealed and highlighted a focus on GC prognosis, the tumor microenvironment (TME), and integrative immunotherapy with targeted therapy. Emerging research areas include gastroesophageal junction cancer, adoptive immunotherapy, and the role of Treg cell in immunotherapy. CONCLUSION:GC immunotherapy research is an expanding field attracting considerable scientific interest. With the clinical adoption of immunotherapy in GC, the primary goals are to enhance treatment efficacy and patient outcomes. Unlike hematological malignancies, GC's solid TME presents distinct immunological challenges that may attenuate the cytotoxic effects of immune cells on cancer cells. For instance, although CAR-T therapy is effective in hematological malignancies, it has underperformed in GC settings. Current research is centered on overcoming immunosuppression within the TME, with a focus on combinations of targeted therapy, adoptive immunotherapy, Treg cell dynamics, and precise prognosis prediction in immunotherapy. Additionally, immunotherapy's role in treating gastroesophageal junction cancer has become a novel research focus.

Peritoneal metastasis (PM) is a terminal stage of gastrointestinal cancers, often resulting in poor survival outcomes. Traditional treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown some effectiveness but are associated with significant risks. This study presents a novel nanomotor-based drug delivery system (M@MnO2-Au-mSiO2@CDDP) designed to enhance the efficacy of PM treatment. By utilizing an oxygen-driven heterojunction nanomotor (MnO2-Au-mSiO2), coated with membrane of M1-type macrophages, the system targets PM tumors with high precision through intraperitoneal perfusion. These biomimetic NMs promote deep tumor penetration, enhance reactive oxygen species (ROS) generation, and activate the STING pathway, a critical component in immune regulation. The catalytic properties of MnO2 within the nanomotors enhance drug permeability and retention, enabling targeted and controlled drug release. Both in vitro and in vivo experiments demonstrated the system's ability to significantly inhibit tumor growth, induce apoptosis, and activate immune responses. In addition, the synergistic effect of targeted drug delivery, catalytic therapy and immunotherapy of this system was further confirmed by constructing an in vitro gastric cancer organoid model, showing great clinical application potential. The study also confirmed excellent biocompatibility and stability, making these NMs a promising clinical tool for the treatment of PM. This research underscores the potential of nanotechnology to revolutionize cancer treatment by overcoming the limitations of traditional therapies and paving the way for future innovations in targeted cancer therapies.

Abstract We report measurements of the absolute branching fractions $$\mathcal{B}\left({B}_{s}^{0}\to {D}_{s}^{\pm }X\right)$$ , $$\mathcal{B}\left({B}_{s}^{0}\to {D}^{0}/{\overline{D} }^{0}X\right)$$ , and $$\mathcal{B}\left({B}_{s}^{0}\to {D}^{\pm }X\right)$$ , where the latter is measured for the first time. The results are based on a 121.4 fb −1 data sample collected at the Υ(10860) resonance by the Belle detector at the KEKB asymmetric-energy e + e − collider. We reconstruct one $${B}_{s}^{0}$$ meson in $${e}^{+}{e}^{-}\to \Upsilon\left(10860\right)\to {B}_{s}^{*}{\overline{B} }_{s}^{*}$$ events and measure yields of $${D}_{s}^{+}$$ , D 0, and D + mesons in the rest of the event. We obtain $$\mathcal{B}\left({B}_{s}^{0}\to {D}_{s}^{\pm }X\right)=\left(68.6\pm 7.2\pm 4.0\right)\%$$ , $$\mathcal{B}\left({B}_{s}^{0}\to {D}^{0}/{\overline{D} }^{0}X\right)=\left(21.5\pm 6.1\pm 1.8\right)\%$$ , and $$\mathcal{B}\left({B}_{s}^{0}\to {D}^{\pm }X\right)=\left(12.6\pm 4.6\pm 1.3\right)\%$$ , where the first uncertainty is statistical and the second is systematic. Averaging with previous Belle measurements gives $$\mathcal{B}\left({B}_{s}^{0}\to {D}_{s}^{\pm }X\right)=\left(63.4\pm 4.5\pm 2.2\right)\%$$ and $$\mathcal{B}\left({B}_{s}^{0}\to {D}^{0}/{\overline{D} }^{0}X\right)=\left(23.9\pm 4.1\pm 1.8\right)\%$$ . For the $${B}_{s}^{0}$$ production fraction at the Υ(10860), we find $${f}_{s}=\left({21.4}_{-1.7}^{+1.5}\right)\%$$ .

We present a measurement of the branching fraction and time-dependent charge-parity (CP) decay-rate asymmetries in B0→J/ψπ0 decays. The data sample was collected with the Belle II detector at the SuperKEKB asymmetric e+e− collider in 2019–2022 and contains (387±6)×106 BB¯ meson pairs from ϒ(4S) decays. We reconstruct 392±24 signal decays and fit the CP parameters from the distribution of the proper-decay-time difference of the two B mesons. We measure the branching fraction to be (B0→J/ψπ0)=(2.00±0.12±0.09)×10−5 and the direct and mixing-induced CP asymmetries to be CCP=0.13±0.12±0.03 and SCP=−0.88±0.17±0.03, respectively, where the first uncertainties are statistical and the second are systematic. We observe mixing-induced CP violation with a significance of 5.0 standard deviations for the first time in this mode. Published by the American Physical Society 2025

A series of data samples was collected with the Belle II detector at the SuperKEKB collider from March 2019 to June 2022. We determine the integrated luminosities of these data samples using three distinct methodologies involving Bhabha (e(+) e(-) -> e(+) e(-)(n gamma)), digamma (e(+) e(-) -> gamma gamma(n gamma)), and dimuon (e(+) e(-) -> mu(+) mu(-)(n gamma)) events. The total integrated luminosity obtained with Bhabha, digamma, and dimuon events is (426.88 +/- 0.03 +/- 2.61) fb(-1), (429.28 +/- 0.03 +/- 2.62) fb(-1), and (423.99 +/- 0.04 +/- 3.83) fb(-1), where the first uncertainties are statistical and the second are systematic. The resulting total integrated luminosity obtained from the combination of the three methods is (427.87 +/- 2.01) fb(-1).

Objective: This study aimed to analyze the prognostic risk factors for hepatoid adenocarcinoma of the stomach (HAS) and construct two nomogram-based clinical prediction models to predict overall survival (OS) and recurrence-free survival (RFS) in patients with HAS. Methods: Data were retrospectively collected from 82 patients (64 males, 18 females; mean age 60.3 ± 9.4 years) who underwent radical gastrectomy and were pathologically diagnosed with gastric hepatoid adenocarcinoma at the First Medical Center of the PLA General Hospital between February 2006 and September 2023. Statistical analyses were conducted using SPSS 25.0 and R 4.3.2. Survival analyses were performed using the Kaplan-Meier method, and univariate analyses were used to identify clinical and pathological factors associated with prognosis. Variables with P<0.05 in the univariate analysis were included in multivariate Cox regression models to identify independent risk factors for OS and RFS. These factors were incorporated into the prediction models to construct nomograms. The discriminatory power of the models was assessed using the area under the curve (AUC) of receiver operating characteristic (ROC) analyses, while calibration curves, decision curve analysis (DCA), and comparisons with the 8th edition of the TNM staging system of the American Joint Committee on Cancer (AJCC) were employed to evaluate model performance. Results: Among the 82 patients, 36 (43.9%) exhibited vascular infiltration, 61 (74.4%) had nerve infiltration, and lymph node metastasis was observed in 60 cases (73.2%). Pathological stages I, II, III, and IV were distributed as 11 (13.4%), 26 (31.7%), 44 (53.7%), and 1 (1.2%) cases, respectively. Inflammatory markers included neutrophil-to-lymphocyte ratio (NLR) ≥ 4.33 in 22 cases (26.8%), platelet-to-lymphocyte ratio (PLR) ≥ 142.2 in 50 cases (61.0%), monocyte-to-lymphocyte ratio (MLR) ≥ 0.411 in 22 cases (26.8%), α-fetoprotein (AFP) ≥ 2.48 µg/L in 64 cases (78.0%), and C-reactive protein (CRP) ≥ 7.506 mg/L in 12 cases (14.6%). Among the 82 patients, 3 cases (3.6%) were lost to follow-up. The median follow-up time was 52 (range: 8-147) months, with a median OS of 61(2-147) months. The 1-year and 3-year OS rates were 78.5% and 58.5%, respectively, while the 1-year and 3-year RFS rates were 77.3% and 60.3%, respectively. Multivariate analysis identified several independent risk factors influencing OS in patients with HAS: advanced pathological stage, MLR ≥ 0.411, AFP ≥ 2.545 µg/L, and CRP ≥ 7.51 mg/L. The hazard ratios (HRs) and 95% confidence intervals (CIs) were as follows: 5.218 (1.230-22.143), 2.610 (1.287-5.294), 2.950 (1.013-8.589), and 2.594 (1.145-5.877), respectively (all P < 0.05). For RFS, advanced pathological stage, PLR ≥ 152.0, and MLR ≥ 0.411 were independent risk factors, with HRs (95% CIs) of 4.735 (1.080-20.760), 3.759 (1.259-11.226), and 2.714 (1.218-6.048), respectively (all P < 0.05). The AUC values for OS prediction at 1 year, 3 years, and 5 years were 0.7765, 0.7525, and 0.7702, respectively. For RFS, the AUC values were 0.7304, 0.8137, and 0.8307 at 1 year, 3 years, and 5 years, respectively. The calibration curves demonstrated strong agreement between nomogram- predicted outcomes and observed survival data. DCA indicated that both TNM staging and the nomogram-based clinical prediction models provided a net positive benefit in predicting OS and RFS in HAS patients, with the nomogram model demonstrating superior performance. Conclusion: The nomogram-based clinical prediction models developed in this study demonstrated robust performance in predicting long-term OS and RFS in patients with HAS.